ATyr Pharma EBIT Margin 2014-2024 | ATYR

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

ATyr Pharma ebit margin from 2014 to 2024. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

ATyr Pharma ebit margin from 2014 to 2024. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$180.5B
Regeneron Pharmaceuticals (REGN)	$126.8B
Vertex Pharmaceuticals (VRTX)	$123.3B
Gilead Sciences (GILD)	$104.5B
Bristol Myers Squibb (BMY)	$99.4B
CSL (CSLLY)	$97.5B
GSK (GSK)	$86.3B
Alnylam Pharmaceuticals (ALNY)	$35.5B
Argenex SE (ARGX)	$32.1B
Biogen (BIIB)	$29.3B
BioNTech SE (BNTX)	$26.8B
Moderna (MRNA)	$26.1B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$19.3B
Genmab (GMAB)	$17.5B
BioMarin Pharmaceutical (BMRN)	$13.6B
Exact Sciences (EXAS)	$13.1B
Vaxcyte (PCVX)	$13.1B
Insmed (INSM)	$12.9B
Incyte (INCY)	$12.9B
Bio-Techne Corp (TECH)	$12.7B
Sarepta Therapeutics (SRPT)	$12.1B
QIAGEN (QGEN)	$10.4B
Legend Biotech (LEGN)	$9.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Ascendis Pharma (ASND)	$8.9B
Roivant Sciences (ROIV)	$8.8B
Repligen (RGEN)	$8.2B
Intra-Cellular Therapies (ITCI)	$8.1B
Exelixis (EXEL)	$7.7B